Guardant Health has developed a method for detecting genetic variants in polynucleotide samples, particularly for melanoma patients. By tagging and sequencing DNA molecules, the presence of specific mutations like BRAF V600E can be identified, allowing for personalized treatment with dabrafenib. GlobalData’s report on Guardant Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Guardant Health Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Guardant Health, Personalized medicine biomarkers was a key innovation area identified from patents. Guardant Health's grant share as of April 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.

Genetic variant detection method for melanoma treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Guardant Health Inc

A recently granted patent (Publication Number: US11959139B2) outlines a method for treating melanoma by detecting a genetic variant associated with a BRAF V600E mutation in a subject and administering therapy comprising dabrafenib based on this detection. The method involves providing a sample containing double-stranded DNA molecules from the subject, attaching molecular barcodes to the DNA molecules, amplifying them, sequencing, mapping, and reducing redundancy in the sequencing reads using sequence information from the barcodes. By detecting the genetic variant associated with the BRAF V600E mutation, the therapy with dabrafenib is administered to treat melanoma effectively.

The patent also includes details on the process, such as the use of double-stranded cell-free DNA molecules in the sample, the tagging of DNA molecules with unique identifiers, and selectively enriching amplified polynucleotides for specific genomic regions of interest, including sequences of the BRAF gene. The method further involves determining quantitative measures of paired and unpaired reads, as well as unseen sequence reads, to calculate the total number of tagged parent polynucleotides accurately. Additionally, an alternative method for treating melanoma involves performing a diagnostic assay on a sample to determine the presence of a genetic variant associated with a BRAF mutation, followed by administering therapy with dabrafenib based on the detection of the mutation. This method also includes steps such as sequencing, mapping, and reducing redundancy in sequencing reads using molecular barcodes, ultimately leading to effective treatment based on genetic variant detection.

To know more about GlobalData’s detailed insights on Guardant Health, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.